Life sciences

The Effect of Scientific Information on Possible Gene-Edited Solutions for Citrus Greening

Retrieved on: 
Friday, February 19, 2021
Articles, Life sciences, Biotechnology, Molecular biology, Biology, Emerging technologies, Biological engineering, Genetic engineering, Citrus greening disease

MILWAUKEE, Feb. 19, 2021 /PRNewswire-PRWeb/ -- The public may not view gene editing very differently than genetic modification and have an initial response that is negative.

Key Points: 
  • MILWAUKEE, Feb. 19, 2021 /PRNewswire-PRWeb/ -- The public may not view gene editing very differently than genetic modification and have an initial response that is negative.
  • In the new article " The Effect of Scientific Information and Narrative on Preferences for Possible Gene-Edited Solutions for Citrus Greening " published in the Applied Economic Perspective & Policy, Brandon McFadden, Kelly Davidson, and John Bernard from the University of Delaware as well as Brittany Anderton from iBiology examine public attitudes toward gene editing and the effects of common communication strategies on support for using gene editing to reduce pests and disease.
  • Therefore, the public may have a more supportive behavioral response to biotechnology than emotional responses would suggest."
  • If you are interested in setting up an interview, please contact Allison Ware in the AAEA Business Office.

Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021

Retrieved on: 
Friday, February 19, 2021
Immune system, Biotechnology, Immunology, Monoclonal antibody, Forward-looking statement, Biology, Life sciences, Articles

The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.

Key Points: 
  • The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.
  • Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
  • Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges.
  • DANYELZA and Y-mAbs are registered trademarks of Y-mAbs Therapeutics, Inc.

Walgreens Administers More than 3 million COVID-19 Vaccinations

Retrieved on: 
Friday, February 19, 2021
Discount, Variety, Infectious diseases, Seniors, Convenience store, Health, Consumer, Pharmaceutical, General Health, Retail, Medical research, Vaccination, Walgreens, Medicine, Life sciences, Medical specialties, Vaccine, COVID-19 vaccine, Discount, Variety, Infectious diseases, Seniors, Convenience store, Health, Consumer, Pharmaceutical, General Health, Retail, Medical research, Vaccination, Walgreens, Medicine, Life sciences, Medical specialties, Vaccine, COVID-19 vaccine

Walgreens has provided more than 3 million COVID-19 vaccinations across long-term care facilities, as well as additional vulnerable populations prioritized by state and local jurisdictions.

Key Points: 
  • Walgreens has provided more than 3 million COVID-19 vaccinations across long-term care facilities, as well as additional vulnerable populations prioritized by state and local jurisdictions.
  • Additionally, the company has completed COVID-19 vaccine first-dose clinics in all long-term care facilities that selected Walgreens as a vaccine provider.
  • In addition to supporting long-term care facilities, Walgreens began in-store vaccinations in 17 states and jurisdictions as part of the Federal Retail Pharmacy Program on Feb. 12.
  • *
    Walgreens also continues to assist several states and jurisdictions with the administration of their COVID-19 vaccine allocations through in-store vaccinations or off-site clinics.

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Friday, February 19, 2021
Life sciences, Biotechnology, Biology, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Molecular biology

CAMBRIDGE,Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences:

Key Points: 
  • CAMBRIDGE,Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences:
    Prerecorded Fireside Chat Available on Tuesday, March 9, 2021 at 7:00 a.m.
  • Audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations.
  • Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need.
  • Fulcrums proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression.

RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Friday, February 19, 2021
Life sciences, Health sciences, Biopharmaceutical, Biotechnology, Pharmaceutical industry, Pharmacy, The Forward Trust

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 12:00 pm Eastern Time.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 12:00 pm Eastern Time.
  • To access the live webcast and subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .
  • RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
  • RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.

Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Retrieved on: 
Friday, February 19, 2021
Life sciences, Biotechnology, SVB Leerink, Biopharmaceutical

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.(Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced thatSharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, 2021at10:00 am ET.

Key Points: 
  • NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.(Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced thatSharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, 2021at10:00 am ET.
  • The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com .
  • Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
  • Intra-Cellular Therapiesis a biopharmaceutical company founded onNobelprize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body.

CytomX Therapeutics Announces New Employment Inducement Grant

Retrieved on: 
Friday, February 19, 2021
Life sciences, Biotechnology, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Two River

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies.

Key Points: 
  • CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies.
  • We are developing a novel class of investigational conditionally-active antibody therapeutics, based on our Probody technology platform, for the treatment of cancer.
  • For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter .
  • Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

Altasciences Acquires WCCT Global

Retrieved on: 
Friday, February 19, 2021
Professional services, Health, Practice Management, Clinical trials, Consulting, Pharmaceutical, Biotechnology, Pharmaceutical industry, Life sciences, Health sciences, Health, WCCT, Contract research organization, Clinical research

Altasciences announced today that they have acquired WCCT Global, Inc. , an early stage clinical research organization, or CRO, located in Southern California on the U.S.A.s West Coast.

Key Points: 
  • Altasciences announced today that they have acquired WCCT Global, Inc. , an early stage clinical research organization, or CRO, located in Southern California on the U.S.A.s West Coast.
  • This acquisition expands Altasciences footprint by providing Phase I and II clinical pharmacology services on the West Coast, and adds 180 beds to our current 400-bed offering.
  • WCCT Global was founded in 1998 and has conducted over 600 Phase I studies an area it specializes in out of over 1,000 Phase I-IV studies the company has conducted to date.
  • Joining the Altasciences team will enhance our offering while allowing us to continue the responsive delivery of quality research data to our global biopharmaceutical clients, stated Gregory Hanson, Executive Chairman, WCCT Global.

Acorda Therapeutics Announces Departure of Chief, Business Operations

Retrieved on: 
Friday, February 19, 2021
Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Acorda Therapeutics, Life sciences, Biotechnology

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that David Lawrence, Chief, Business Operations and its principal accounting and financial officer, is resigning from the Company effective mid-March, 2021.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that David Lawrence, Chief, Business Operations and its principal accounting and financial officer, is resigning from the Company effective mid-March, 2021.
  • While we will miss him, we support his interest in exploring a new phase of his career, and wish him well in his next opportunity.
  • Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.

Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2021 Financial Results

Retrieved on: 
Friday, February 19, 2021
Branches of biology, Stem cells, Biology, Life sciences, Cord blood bank, Cord blood, Umbilical cord, Hematopoietic stem cell, Cordlife, LifeCell International

HONG KONG, Feb. 19, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the thirdquarter and first nine months of fiscal year 2021 on Wednesday, February 24, 2021, after the U.S. market close.

Key Points: 
  • HONG KONG, Feb. 19, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the thirdquarter and first nine months of fiscal year 2021 on Wednesday, February 24, 2021, after the U.S. market close.
  • ET on Thursday, February 25, 2021 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session.
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.
  • Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.